The Trump administration announced this week that it will continue a Biden-era policy of negotiating lower medication costs for Medicare Part D recipients.

The Inflation Reduction Act, passed by Congress in 2022, allowed Medicare to negotiate drug prices. The law also set a $2,000 annual cap on out-of-pocket drug expenses for Medicare Part D enrollees.

After the federal government announced price caps on 10 popular medications in 2024, the Centers for Medicare & Medicaid Services said Tuesday it has negotiated lower prices for 15 drugs.

The 10 drugs that the Biden administration said would be subject to price caps are scheduled to take effect in 2026. The 15 drugs announced by the Trump administration could see lower prices in 2027.

Among the medications the Centers for Medicare & Medi

See Full Page